Published in Cancer Weekly, December 16th, 1996
The patent provides additional protection against unauthorized making, importation, use, or sale of recombinant G-CSF in the United States. The patent provides 17 years of such protection. Previous patents cover aspects of DNA, vectors, and processes related to recombinant G-CSF.
"This new patent provides additional, broad patent protection and strengthens our intellectual property position on Neupogen," said Gordon Binder, Amgen. Neupogen is licensed in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly